A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

被引:268
作者
Farlow, M
Anand, R
Messina, J
Hartman, R
Veach, J
机构
[1] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
[2] Novartis Pharmaceut Corp, Dept Med Affairs CNS, E Hanover, NJ USA
[3] Novartis Pharmaceut Corp, Dept Stat, E Hanover, NJ USA
关键词
cholinesterase inhibitor; rivastigmine; clinical trial; Alzheimer's disease;
D O I
10.1159/000008243
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon(R)), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG., Basel.
引用
收藏
页码:236 / 241
页数:6
相关论文
共 10 条
  • [1] [Anonymous], 1998, Int J Geriatr Psychopharmacol
  • [2] Cutler NR, 1998, ACTA NEUROL SCAND, V97, P244
  • [3] Cholinergic markers in elderly patients with early signs of Alzheimer disease
    Davis, KL
    Mohs, RC
    Marin, D
    Purohit, DP
    Perl, DP
    Lantz, M
    Austin, G
    Haroutunian, V
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (15): : 1401 - 1406
  • [4] ENZ A, 1993, PROG BRAIN RES, V98, P431
  • [5] KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458
  • [7] LEBER P, 1997, ALZHEIMER DIS ASS S5, V11, P10
  • [8] ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356
  • [9] Efficacy and safety of rivastigmine in patients with Alzheimer's disease:: international randomised controlled trial
    Rösler, M
    Anand, R
    Cicin-Sain, A
    Gauthier, S
    Agid, Y
    Dal-Bianco, P
    Stähelin, HB
    Hartman, R
    Gharabawi, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7184): : 633 - 638
  • [10] STERN RG, 1994, AM J PSYCHIAT, V151, P390